None listed
Conditions
Interventions
Drug : After induction of anesthesia, patients in Group N will receive nefopam 0.3 mg/kg as an intravenous bolus, followed by continuous infusion at 65 µg/kg/h. Patients in Group K will receive ketami
Sponsors
Yeongnam University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Undergoing transurethral resection of bladder tumor 2) American Society of Anesthesiologists (ASA) physical status classification I and II
Exclusion criteria
Exclusion criteria: i) Patients with severe systemic disease classified as American Society of Anesthesiologists (ASA) physical status = 3 ii) Patients with allergy to any study medication iii) Patients with urinary retention or overactive bladder (urinary frequency >3 times/night or >8 times/24 h) iv) Patients with epilepsy, seizure disorder, myocardial infarction, arrhythmia, heart failure, renal or hepatic disease, or current use of monoamine oxidase (MAO) inhibitors v) Patients with angle-closure glaucoma vi) Patients with a history of drug or alcohol abuse vii) Patients receiving opioid or sedative therapy viii) Patients with hypersensitivity to anesthetic agents used in the study ix) Patients with morbid obesity (body mass index >30 kg/m²) x) Pregnant or breastfeeding women xi) Patients with chronic pain, neurologic disorders, or psychiatric disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of postoperative catheter-related bladder discomfort ? | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain scores and demand for analgesics;Postoperative nausea and vomiting severity, cold sweat, dry mouth, shivering, dizziness, drowsiness, headache, blurred vision (occurrence);Quality of Recovery assessment (QoR-15) | — |
Countries
Korea, Republic of
Contacts
Public Contacteun kyung choe
Yeongnam University Medical Center
Outcome results
None listed